FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016928596> ?p ?o ?g. }

• W2016928596 endingPage "41451" @default.
• W2016928596 startingPage "41443" @default.
• W2016928596 abstract "The Toll/interleukin 1 receptor (TIR) domain is a region found in the cytoplasmic tails of members of the Toll-like receptor/interleukin-1 receptor superfamily. The domain is essential for signaling and is also found in the adaptor proteins Mal (MyD88 adaptor-like) and MyD88, which function to couple activation of the receptor to downstream signaling components. Experimental structures of two Toll/interleukin 1 receptor domains reveal a α–β-fold similar to that of the bacterial chemotaxis protein CheY, and other evidence suggests that the adaptors can make heterotypic interactions with both the receptors and themselves. Here we show that the purified TIR domains of Mal and MyD88 can form stable heterodimers and also that Mal homodimers and oligomers are dissociated in the presence of ATP. To identify structural features that may contribute to the formation of signaling complexes, we produced models of the TIR domains from human Toll-like receptor 4 (TLR4), Mal, and MyD88. We found that although the overall fold is conserved the electrostatic surface potentials are quite distinct. Docking studies of the models suggest that Mal and MyD88 bind to different regions in TLRs 2 and 4, a finding consistent with a cooperative role of the two adaptors in signaling. Mal and MyD88 are predicted to interact at a third non-overlapping site, suggesting that the receptor and adaptors may form heterotetrameric complexes. The theoretical model of the interactions is supported by experimental data from glutathione S-transferase pull-downs and co-immunoprecipitations. Neither theoretical nor experimental data suggest a direct role for the conserved proline in the BB-loop in the association of TLR4, Mal, and MyD88. Finally we show a sequence relationship between the Drosophila protein Tube and Mal that may indicate a functional equivalence of these two adaptors in the Drosophila and vertebrate Toll pathways. The Toll/interleukin 1 receptor (TIR) domain is a region found in the cytoplasmic tails of members of the Toll-like receptor/interleukin-1 receptor superfamily. The domain is essential for signaling and is also found in the adaptor proteins Mal (MyD88 adaptor-like) and MyD88, which function to couple activation of the receptor to downstream signaling components. Experimental structures of two Toll/interleukin 1 receptor domains reveal a α–β-fold similar to that of the bacterial chemotaxis protein CheY, and other evidence suggests that the adaptors can make heterotypic interactions with both the receptors and themselves. Here we show that the purified TIR domains of Mal and MyD88 can form stable heterodimers and also that Mal homodimers and oligomers are dissociated in the presence of ATP. To identify structural features that may contribute to the formation of signaling complexes, we produced models of the TIR domains from human Toll-like receptor 4 (TLR4), Mal, and MyD88. We found that although the overall fold is conserved the electrostatic surface potentials are quite distinct. Docking studies of the models suggest that Mal and MyD88 bind to different regions in TLRs 2 and 4, a finding consistent with a cooperative role of the two adaptors in signaling. Mal and MyD88 are predicted to interact at a third non-overlapping site, suggesting that the receptor and adaptors may form heterotetrameric complexes. The theoretical model of the interactions is supported by experimental data from glutathione S-transferase pull-downs and co-immunoprecipitations. Neither theoretical nor experimental data suggest a direct role for the conserved proline in the BB-loop in the association of TLR4, Mal, and MyD88. Finally we show a sequence relationship between the Drosophila protein Tube and Mal that may indicate a functional equivalence of these two adaptors in the Drosophila and vertebrate Toll pathways. In humans, innate immune responses provide the first line of defense against invading bacterial pathogens. Pathogen-associated molecular patterns such as lipopolysaccharide (LPS) 1The abbreviations used are: LPS, lipopolysaccharide; TLR, Toll-like receptor; TIR, Toll/interleukin 1 receptor domain; Mal, MyD88 adaptor-like; HEK, human embryonic kidney; HA, hemagglutinin; GST, glutathione S-transferase; P/H, proline to histidine mutation. from Gram-negative bacteria are sensed by macrophages, and these cells respond by producing pro-inflammatory cytokines (e.g. interleukin 1), which provoke the acute phase response to infection (for review see Ref. 1Dunne, A., and O'Neill, L. A. (2003) Science's STKE http://stke.sciencemag.org/cgi/content/full/sigtrans;2003/171/re3.Google Scholar). In recent years, it has become clear that the human Toll-like receptors (TLRs) are required to mediate these responses. These molecules are single pass transmembrane receptors, and they are related to Drosophila Toll, a protein involved in dorso-ventral patterning and antifungal innate immunity in the fly (2Gay N.J. Keith F.J. Nature. 1991; 351: 355-356Crossref PubMed Scopus (457) Google Scholar, 3Belvin M.P. Anderson K.V. Annu. Rev. Cell. Dev. Bi. 1996; 12: 393-416Crossref PubMed Scopus (690) Google Scholar, 4Imler J.L. Hoffmann J.A. Trends Cell Biol. 2001; 11: 304-311Abstract Full Text Full Text PDF PubMed Scopus (355) Google Scholar). Drosophila Toll and TLRs all have ectodomains with characteristic blocks of leucine-rich repeats and a cytoplasmic signaling domain of ∼200 residues called the Toll/interleukin 1 receptor (TIR) domain. The family of Toll receptors appears to use common components in the post-receptor signaling pathway, resulting in the activation of the transcription factor NFκB (5Buchanan S.G.S. Gay N.J. Prog. Biophys. Mol. Biol. 1996; 65: 1-44Crossref PubMed Google Scholar, 6Rock F.L. Hardiman G. Timans J.C. Kastelein R.A. Bazan J.F. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 588-593Crossref PubMed Scopus (1457) Google Scholar). It is now well established that human TLR4 together with two other membrane proteins CD14 and MD2 are able to sense the presence of LPS and to establish the appropriate signaling response (7Triantafilou M. Triantafilou K. Trends Immunol. 2002; 23: 301-304Abstract Full Text Full Text PDF PubMed Scopus (599) Google Scholar). For example, strains of mice that are hyposensitive to LPS either lack or have inactivating mutations in TLR4 (8Poltorak A. He X.L. Smirnova I. Liu M.Y. Van Huffel C. Du X. Birdwell D. Alejos E. Silva M. Galanos C. Freudenberg M. Ricciardi-Castagnoli P. Layton B. Beutler B. Science. 1998; 282: 2085-2088Crossref PubMed Scopus (6473) Google Scholar). Activation of the receptor is thought to involve dimerization followed by recruitment of a post-receptor complex containing the adaptor MyD88 and the protein kinase IRAK (interleukin 1 receptor-associated kinase) (9Wesche H. Henzel W.J. Shillinglaw W. Li S. Cao Z.D. Immunity. 1997; 7: 837-847Abstract Full Text Full Text PDF PubMed Scopus (922) Google Scholar). MyD88 is a critical component in the pathway and is required by most if not all of the TLRs (10Kawai T. Adachi O. Ogawa T. Takeda K. Akira S. Immunity. 1999; 11: 115-122Abstract Full Text Full Text PDF PubMed Scopus (1735) Google Scholar). It is a modular protein with a TIR and protein interaction domain termed the death domain (11Hardiman G. Rock F.L. Balasubramanian S. Kastelein R.A. Bazan J.F. Oncogene. 1996; 13: 2467-2475PubMed Google Scholar). The TIR domain is thought to bind with that of the receptor, and the death domain appears to interact with the death domain found at the N terminus of IRAK. Although MyD88 is the principal transducer of TLR signaling, the TLR4 pathway appears to have evolved a second adaptor called Mal (MyD88 adaptor-like) or TIRAP (TIR adaptor protein) (12Fitzgerald K.A. Palsson-McDermott E.M. Bowie A.G. Jefferies C.A. Mansell A.S. Brady G. Brint E. Dunne A. Gray P. Harte M.T. McMurray D. Smith D.E. Sims J.E. Bird T.A. O'Neill L.A.J. Nature. 2001; 413: 78-83Crossref PubMed Scopus (1002) Google Scholar, 13Horng T. Barton G.M. Medzhitov R. Nat. Immunol. 2001; 2: 835-841Crossref PubMed Scopus (830) Google Scholar). Similar to MyD88, this protein has a TIR but it lacks a death domain. In Drosophila, a clear homologue of MyD88 is involved in the Toll-mediated innate immune responses (14Horng T. Medzhitov R. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 12654-12658Crossref PubMed Scopus (216) Google Scholar, 15Tauszig-Delamasure S. Bilak H. Capovilla M. Hoffmann J.A. Imler J.L. Nat. Immunol. 2002; 3: 91-97Crossref PubMed Scopus (239) Google Scholar). However, in dorso-ventral patterning, a different adaptor, Tube, is used. Similar to MyD88, this protein has an N-terminal death domain but it lacks an obvious TIR domain (16Letsou A. Alexander S. Orth K. Wasserman S.A. Proc. Natl. Acad. Sci. U. S. A. 1991; 88: 810-814Crossref PubMed Scopus (95) Google Scholar). There is now consistent biochemical evidence that activation of TLRs involves the recruitment of specific post-receptor signaling complexes. However, there is still only limited structural information regarding these complexes. In fact, the only structures solved to date are those of the isolated TIRs from TLRs 1 and 2 (17Xu Y.W. Tao X. Shen B.H. Horng T. Medzhitov R. Manley J.L. Tong L. Nature. 2000; 408: 111-115Crossref PubMed Scopus (233) Google Scholar). These molecules have an overall fold with a central five-stranded parallel β-sheet surrounded by five helices. The structures are related to the bacterial chemotaxis protein CheY, confirming a prediction made by Bazan et al., (6Rock F.L. Hardiman G. Timans J.C. Kastelein R.A. Bazan J.F. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 588-593Crossref PubMed Scopus (1457) Google Scholar, 18Simonovic M. Volz K. J. Biol. Chem. 2001; 276: 28637-28640Abstract Full Text Full Text PDF PubMed Scopus (63) Google Scholar). Most of the conserved residues in TIR domains are buried in the core of the fold, but some are solvent-exposed residues located on one face of the protomer. This may form an interaction surface to which MyD88 and Mal can bind in response to signaling. In fact, a loop termed the BB-loop connecting the second β-strand and second helix includes a proline residue that is changed to histidine in mice, which are hyporesponsive to LPS, and the corresponding change also abolishes the ability of TLR2 to interact with MyD88 in vitro (8Poltorak A. He X.L. Smirnova I. Liu M.Y. Van Huffel C. Du X. Birdwell D. Alejos E. Silva M. Galanos C. Freudenberg M. Ricciardi-Castagnoli P. Layton B. Beutler B. Science. 1998; 282: 2085-2088Crossref PubMed Scopus (6473) Google Scholar, 17Xu Y.W. Tao X. Shen B.H. Horng T. Medzhitov R. Manley J.L. Tong L. Nature. 2000; 408: 111-115Crossref PubMed Scopus (233) Google Scholar). In this paper, we have modeled the TIR domains of TLR4, MyD88, and Mal. Experimental data are provided to support results obtained from docking studies, and putative interaction motifs are identified with particular attention being paid to the conserved proline residue found within the BB-loop of the receptor and adaptor TIR domains. These structures suggest mechanisms by which binding and specificity are achieved by different combinations of TIRs during signaling We also report sequence similarities between Mal and the Drosophila adaptor Tube and the ATP-dependent dissociation of Mal dimers and oligomers. Modeling Studies—The sequences of target proteins were extracted from the protein sequence data banks. Sequence homologues were retrieved using PSI-BLAST and aligned using ClustalW. The resulting alignment was carefully studied and further adjusted manually using a UNIX-based sequence alignment editor, SEAVIEW. Percentage similarities between homologues were scored using MALFORM. Homologues with known three-dimensional structures were aligned using COMPARER (19Sali A. Blundell TL. J. Mol. Biol. 1990; 212: 403-428Crossref PubMed Scopus (481) Google Scholar) or FuGue (20Shi J. Blundell T.L. Mizuguchi K. J. Mol. Biol. 2001; 310: 243-257Crossref PubMed Scopus (1085) Google Scholar). The JOY annotation used in structure based sequence alignments has been described previously (21Mizuguchi K. Deane C.M. Blundell T.L. Johnson M.S. Overingon J.P. Bioinformatics. 1998; 14: 617-623Crossref PubMed Scopus (358) Google Scholar, 22Burke D.F. Deane C.M. Nagarajaram H.A. Campillo N. Martin-Martinez M. Mendes J. Molina F. Perry J. Reddy B.V.B. Soares C.M. Steward R.E. Williams M. Carrondo M.A. Blundell T.L. Mizuguchi K. Proteins. 1999; : 55-60Crossref PubMed Scopus (40) Google Scholar). The target sequence was then aligned to the structure based alignment using ClustalX. This alignment was conducted such that gaps or insertions within conserved secondary structure regions are disfavored by constructing a SWISS-PROT style secondary structure mask. MODELLER6a was used to generate 15 models for each protein. Five models with the best combination of low energy and low number of restraint violations were chosen. PROCHECK was used to check the stereochemical quality of models (23Laskowski R.A. Macarthur M.W. Moss D.S. Thornton J.M. J. Appl. Crystallogr. 1993; 26: 283-291Crossref Google Scholar, 24Morris A.L. Macarthur M.W. Hutchinson E.G. Thornton J.M. Proteins. 1992; 12: 345-364Crossref PubMed Scopus (1417) Google Scholar). Loop regions with residue geometry problems were further modeled using RAPPER (25de Bakker P. DePristo M. Burke D. Blundell T. Proteins. 2003; 51: 21-40Crossref PubMed Scopus (125) Google Scholar, 26DePristo M. de Bakker P. Lovell S. Blundell T. Proteins. 2003; 51: 41-55Crossref PubMed Scopus (120) Google Scholar). Models were analyzed further using PROSAII 3.0 or Verify 3D, which use Cα- and Cβ-based potentials to calculate energy profiles for protein structures. Models of complexes between TLR4 and the adaptor proteins, Mal and Myd88, were constructed using geometry and hydrophobicity complementarity search algorithm in GRAMM. The docking parameters were step grid at 6.8 Å, repulsion potential at 6.5, and intervals of rotation at 10°. One hundred models were generated, and the twenty lowest energy matches were analyzed. Cell Culture, Plasmids, and Reagents—HEK293 cells were obtained from the Centre for Applied Microbiology & Research (CAMR, Porton Down, Salisbury, Wiltshire, United Kingdom) and were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 units ml–1 gentamycin, and 2 mm l-glutamine and maintained at 37 °C in a humidified atmosphere of 5% CO2. HEK293 cells stably expressing FLAG-tagged TLR-4 were a generous gift from Douglas Golenbock. Cells were seeded at 105 ml–1 24 h prior to transfection. The FLAG-tagged TLR4-expressing plasmid was a kind gift from Ruslan Medzhitov (Yale University School of Medicine, New Haven, CT). The MyD88-expressing plasmid was a gift from Marta Muzio (Mario Negri Institute, Milan, Italy). HA-tagged Mal from the pDC304 vector was subcloned into the pCDNA3 expression vector for mammalian cell-based transfections. For bacterial expression, cDNAs encoding full-length Mal, MyD88, and the TIR domain of TLR4 were amplified by PCR using a spleen library and cloned into the BamHI and EcoRI sites of pGEX-4T2 (Amersham Biosciences). Point mutations were generated using the QuikChange site-directed mutagenesis kit (Stratagene) according the protocol of the manufacturer. All of the other reagents were obtained from Sigma (Poole, Dorset, United Kingdom) unless otherwise stated. Co-expression and Purification of Mal and MyD88 —Mal and Myd88 full-length expression vectors were co-transformed into Escherichia coli BL21 (DE3) and grown in Luria broth. A bacterial cell culture was grown to A 600 = 0.6 under ampicillin and kanamycin selection. Protein expression was induced with 0.7 mm isopropyl-1-thio-β-d-galactopyranoside. Bacterial cells were harvested and resuspended in 50 mm Tris buffer, pH 7.6, 0.15 m NaCl, 5 mm dithiothreitol, 5 mm EDTA, 0.01% Triton X-100, EDTA-free protease inhibitor mixture (Roche Applied Science). Cells were lysed in the French press at 15000 p.s.i., and the soluble/insoluble fractions were separated by centrifugation at 100,000 × g. Protein purification was facilitated by affinity purification on glutathione-Sepharose, anion-exchange and size exclusion chromatography (fast protein liquid chromatography). Immunoprecipitation and GST Pull-down Assays—HEK293 cells were seeded (105 ml–1) onto 100-mm dishes 24 h prior to transfection with combinations of plasmids (4 μg of each) as indicated using Genejuice (Novagen) according to the manufacturer's recommendations. 24–48-h post-transfection cells were washed by the addition of 5 ml of ice-cold phosphate-buffered saline. Cells were lysed on ice (30 min) in buffer containing 150 mm NaCl, 2 mm EDTA, 10% glycerol, 1% Nonidet P-40, 0.2 mm phenylmethylsulfonyl fluoride, 0.2 mm Na3VO4, and 1 μg of leupeptin ml–1. Immune complexes were immunoprecipitated by incubation for 2 h at 4 °C with the appropriate antibody, which had been pre-coupled to protein G-Sepharose at 4 °C overnight. The immune complexes were washed three times in lysis buffer, separated by SDS-PAGE, and then analyzed by Western blotting. GST pull-down assays were performed using the recombinant GST fusion proteins coupled to GSH-Sepharose. Lysis extracts were prepared as described above and incubated for 2 h with the fusions indicated in the figure legends. The complexes were washed three times in lysis buffer and subjected to SDS-PAGE and Western blotting. Monoclonal antibodies against the epitope tags FLAG (12CA5) and Myc (9E10) were obtained from Sigma. The polyclonal antibody against the HA epitope tag (Y-11) was obtained from Santa Cruz Biotechnology. The monoclonal AU1 antibody was obtained from Berkeley Antibody Company. The polyclonal antibody against human TLR4 was a kind gift from Keith Ray (Glaxo Wellcome, Stevenage, United Kingdom). Molecular Modeling of TLR4, Mal, and MyD88 TIR Domains—The evidence suggests that TIR domains from receptors and adaptors are likely to form multitypic complexes. To study how this might occur, we used the crystal structures of the TIR domain from TLRs 1 and 2 (17Xu Y.W. Tao X. Shen B.H. Horng T. Medzhitov R. Manley J.L. Tong L. Nature. 2000; 408: 111-115Crossref PubMed Scopus (233) Google Scholar) to generate molecular models for TLR4, Mal, and MyD88 TIR domains. Structure-based alignments of experimental structures to target sequences generated by FUGUE and COMPARER were used by MODELLER6a for comparative modeling (data not shown). The loop regions were refined using RAPPER (25de Bakker P. DePristo M. Burke D. Blundell T. Proteins. 2003; 51: 21-40Crossref PubMed Scopus (125) Google Scholar, 26DePristo M. de Bakker P. Lovell S. Blundell T. Proteins. 2003; 51: 41-55Crossref PubMed Scopus (120) Google Scholar). Model evaluation using Procheck and PROSAII revealed that the domains were modeled with no structural violations. Electrostatic surface representations of the experimental structure of TLRs 1 and 2 and the models of TLR4, Mal, and MyD88 are shown in Fig. 1 oriented to show the “S” face. This surface has a number of conserved solvent-exposed residues including the critical Pro residue in the BB-loop. Interestingly, apart from this area the electrostatic surface potentials are quite distinct, suggesting the possibility of electrostatic complementarity. The regions on the upper left and lower right of the BB-loop are the most interesting. For example, in TLR4, the upper left is positively charged (Arg-705), whereas the corresponding region in Mal is negatively charged (Asp-154). Another characteristic of Mal that differentiates it from TLR4 and MyD88 is the lack of conservation in “box 3,” a sequence at the C-terminal of the TIR (see Ref. 12Fitzgerald K.A. Palsson-McDermott E.M. Bowie A.G. Jefferies C.A. Mansell A.S. Brady G. Brint E. Dunne A. Gray P. Harte M.T. McMurray D. Smith D.E. Sims J.E. Bird T.A. O'Neill L.A.J. Nature. 2001; 413: 78-83Crossref PubMed Scopus (1002) Google Scholar). This region is located at the bottom right of the models and in Mal results in a distinct electrostatic surface (Fig. 1e). As noted above, TLR4, Mal, and MyD88 are able to make heterotypic interactions with each other and these surface properties may indicate how binding specificity is achieved in the post-receptor complex. In an attempt to map the interaction surface for TLR4 with Mal and Myd88, we docked the adaptor proteins onto the TLR4 model using GRAMM (27Katchalski-Katzir E. Shariv I. Eisenstein M. Friesem A.A. Aflalo C. Vakser I.A. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 2195-2199Crossref PubMed Scopus (865) Google Scholar, 28Vakser I.A. Protein Eng. 1995; 8: 371-377Crossref PubMed Scopus (223) Google Scholar, 29Wells C.A. Vakser I.A. Protein Sci. 2002; 11: 1888-1896Crossref PubMed Scopus (88) Google Scholar). GRAMM docking was conducted on the basis of hydrophobicity and geometry. Models of the best scoring heterotypic complexes of TLR4 with Mal and MyD88 are presented in Fig. 2a. Interestingly, this study suggests non-overlapping binding sites on TLR4 for Mal and MyD88. Mal is predicted to associate through its DD- and DE-loops with the positively charged region of TLR4 centered on Arg-705. This region on TLR4 contains one side of the BB-loop and the αC helix and corresponds to the upper left-hand region in Fig. 1d. MyD88 is predicted to bind with a surface created by its AA- and DD-loop to the CD-loop on TLR4, which is located on the other side of the receptor, opposite its BB-loop. Docking studies with the experimental structure of TLR2 suggest that both adaptors couple to the same surface on this receptor (Fig. 2b). In this case, Myd88 coupling is distinct from that seen with TLR4 with the BB-loop of TLR2 forming a possible point of contact between the two proteins. Effect of the Mutation Conferring Dominant LPS Sensitivity on Receptor/Adaptor Interactions—Previous modeling studies are comparable with those described above and also represent the BB-loop of TLR4 as an exposed surface area (30Ronni T. Agarwal V. Haykinson M. Haberland M.E. Cheng G. Smale S.T. Mol. Cell. Biol. 2003; 23: 2543-2555Crossref PubMed Scopus (50) Google Scholar). Residues within this loop are critical for TLR4 signaling as displayed by the C3H/HeJ mice, which are unresponsive to LPS because of an inactivating proline to histidine mutation at position 712. Mutation of the corresponding residue in human TLR4 (P714H) also renders the receptor inactive and is thought to disrupt MyD88/TLR4 complex formation. This is based on interaction studies with human TLR2 in which the adaptor failed to immunoprecipitate with the mutant receptor (17Xu Y.W. Tao X. Shen B.H. Horng T. Medzhitov R. Manley J.L. Tong L. Nature. 2000; 408: 111-115Crossref PubMed Scopus (233) Google Scholar). According to our model, the P/H mutation should not affect MyD88/TLR4 heterodimerization. Therefore, we carried out similar experiments to clarify whether this is in fact the case. As shown in Fig. 3, a and b, the TLR4 P/H mutant retained the ability to bind to MyD88 in both co-immunoprecipitation and GST pull-down assays. Both the wild type and mutant forms of TLR4 were also found to bind to Mal in reciprocal GST pull-down assays and co-immunoprecipitations (Fig. 3, c–e). This confirms findings from previously reported immunoprecipitations experiments (12Fitzgerald K.A. Palsson-McDermott E.M. Bowie A.G. Jefferies C.A. Mansell A.S. Brady G. Brint E. Dunne A. Gray P. Harte M.T. McMurray D. Smith D.E. Sims J.E. Bird T.A. O'Neill L.A.J. Nature. 2001; 413: 78-83Crossref PubMed Scopus (1002) Google Scholar, 13Horng T. Barton G.M. Medzhitov R. Nat. Immunol. 2001; 2: 835-841Crossref PubMed Scopus (830) Google Scholar). Furthermore, a direct interaction was observed between wild type and mutant TLR4 and Mal when the purified recombinant proteins were incubated in isolation (Fig. 3f). A corresponding proline residue is also found in the BB-loops of Mal and MyD88. Therefore, we tested the ability of mutant forms of the adaptors to bind to TLR4. As shown in Fig. 4, a and b, the MyD88 P200H mutation has no effect on TLR4/MyD88 heterodimerization and is consistent with our model in which the BB-loop of MyD88 does not form a point of contact with the receptor TIR domain. It was previously reported that the Mal P125H mutant (which fails to activate NFκB) cannot bind to TLR4 (13Horng T. Barton G.M. Medzhitov R. Nat. Immunol. 2001; 2: 835-841Crossref PubMed Scopus (830) Google Scholar); however, in our hands, an interaction was observed between the two proteins in co-immunoprecipitation and GST pull-down experiment (Fig. 4c). Again, this is consistent with our model in which the BB-loop of Mal is directed away from the receptor. Mal and MyD88 Heterodimerization—GRAMM docking predicts that Mal and MyD88 TIRs interact with each other at a third non-overlapping site (Fig. 5a). This interface produces an essentially symmetrical arrangement of the Mal and MyD88 protomers with hydrophobic residues at the end of the BB-loop (Ile-30 and Val-205, respectively) together with polar residues on the fourth α helix (Gln-153, Asp-154 in Mal, and Gln-230 in MyD88 in Fig. 5a) making significant contributions. To address whether this interaction is direct, we co-expressed a His-tagged version of full-length Myd88 and GST-tagged full-length Mal in E. coli BL21(DE3) cells (Fig. 5b, lanes 1–3). The two proteins were purified by affinity chromatography on a glutathione-Sepharose column. After extensive washing, the bound proteins were eluted by thrombin cleavage. Myd88 was observed to co-elute with Mal (Fig. 5b, lanes 4–7). Mutation of Pro-125 in Mal had no effect on the association of Mal with itself or with MyD88 in pull-down and co-immunoprecipitation experiments (Fig. 5, c and e). Likewise, mutation of the corresponding proline residue in MyD88 (P200H) did not prevent its homodimerization as shown in Fig. 5d. Importantly, a construct consisting only of the TIR domain of MyD88 was used in these experiments to rule out any N-terminal interactions that may be mediated by the death domain of MyD88. ATP-dependent Dissociation of Mal Dimers and Oligomers— When studying some of the homotypic and heterotypic interactions described above, the TIR domains of Mal and MyD88 were expressed in E. coli (see “Experimental procedures”). As a final step of purification, the Mal and MyD88 preparations were fractionated by gel-filtration chromatography on Superdex 75 16/60. This analysis revealed an unexpected adenine nucleotide-dependent behavior by Mal. Soluble fractions of induced cells were prepared in either the presence or absence of 1 mm ATP, a treatment reported to remove a contaminant that otherwise co-purifies with GST fusion proteins. The extracts were then purified as described above and finally separated by gel filtration. As shown in Fig. 6, untreated Mal elutes in three well resolved peaks, all of which consist of pure Mal protein. By contrast, Mal purified from ATP-treated lysates migrates as a single peak. This result was reproduced in several experiments and was not observed with corresponding MyD88 TIR domain preparations (data not shown). Sequence Relationship between Mal and the Drosophila Adaptor Tube—The adaptors dMyD88 and Tube are known to couple to the Drosophila receptor, Toll. Because dMyD88 is a direct homolog of vertebrate MyD88, we asked whether Mal might be related to Tube. We generated an alignment between the two proteins using ClustalW and found that the N-terminal sequence of Mal immediately preceding the TIR domain is strikingly similar to the C-terminal of Tube adjacent to the death domain (Fig. 7). 30 of 80 amino acids in this region are conserved or conservatively substituted. These amino acids are also highly conserved in the Tube sequence from the distantly related dipteran Drosophila virilis (31Letsou A. Alexander S. Wasserman S.A. EMBO J. 1993; 12: 3449-3458Crossref PubMed Scopus (39) Google Scholar). The C-terminal of Tube is also aligned by ClustalW with 47 identities or conservative substitutions in the last 150 amino acids. The most conserved regions correspond to the predicted β-strands in the TIR models and particularly hydrophobic core residues. Thus, it seems possible that the Tube C terminus might represent a highly degenerated member of the TIR-fold family, consistent with its role in coupling activation and signaling by the Drosophila Toll receptor. The modeling and docking studies presented here suggest that there are discrete sites on the receptor TIR domains for binding Mal and MyD88 and a third mode of binding for the formation of Mal/MyD88 heterodimers. Neither of the predicted interactions of the adaptor TIR domains appears to directly involve the BB-loop region on TLR4, although that predicted for Mal is immediately adjacent to it. In vitro assays confirm that mutation of a critical proline residue, which lies at the tip of the BB-loop is not sufficient to prevent recruitment of the adaptor proteins. This result contrasts with the finding that mutation of the corresponding residue in TLR2 abolishes the binding of MyD88. Importantly, there are no significant structural differences between the wild type and mutant TLR2 protein (17Xu Y.W. Tao X. Shen B.H. Horng T. Medzhitov R. Manley J.L. Tong L. Nature. 2000; 408: 111-115Crossref PubMed Scopus (233) Google Scholar), and this is probably the case with TLR4. Of course, we cannot rule out the possibility that MyD88 is recruited to the mutant receptor via endogenous Mal should the latter bind at a distinct surface. It may also be the case that mutation of a single residue within the BB-loop is not sufficient to prevent receptor/adaptor association. Indeed, a recent report providing a detailed examination of interaction surfaces on the TLR4 TIR domain revealed that amino acids in both the BB- and DD-loops on TLR4 are critical for signaling (30Ronni T. Agarwal V. Haykinson M. Haberland M.E. Cheng G. Smale S.T. Mol. Cell. Biol. 2003; 23: 2543-2555Crossref PubMed Scopus (50) Google Scholar). In addition, the program GRAMM uses a rigid docking procedure and would not be able to predict sites that undergo a significant conformational change on binding. Thus, if the BB-loop is directly involved in binding, it may undergo a switch such as that seen upon the binding of vonWillebrand factor to platelet glycoprotein 1B (Gp1B) (32Huizinga E.G. Tsuji S. Romijn R.A.P. Schiphorst M.E. de Groot P.G. Sixma J.J. Gros P. Science. 2002; 297: 1176-1179Crossref PubMed Scopus (503) Google Scholar). In this case, a 16 amino acid loop in Gp1B becomes a β-hairpin and this forms part of a three-stranded intermolecular antiparallel β-sheet. In support of this finding, a recent study of a mutant TLR2 TIR domain, which assumes a somewhat different conformation to that in the original crystal structure, indicates that the BB-loop is intrinsically flexible (33Tao X. Xu Y.W. Zheng Y. Beg A.A. Tong L. Biochem. Biophys. Res. Commun. 2002; 299: 216-221Crossref PubMed Scopus (99) Google Scholar). The BB-loops of the adaptors appear also not to form a point of contact with either TLR4 or themselves in both docking and experimental studies. Again, we cannot rule out the possibility that the mutant proteins are recruited to the receptor complex by their endogenous wild type counterparts. Direct measurement of protein-protein interactions is required to determine the validity of these models. We have expressed and purified Mal and MyD88 to study them biochemically. We have shown that heterodimers of MyD88 and Mal can be reconstituted in a purified system consistent with previous results using immunoprecipitation and yeast two-hybrid assays (12Fitzgerald K.A. Palsson-McDermott E.M. Bowie A.G. Jefferies C.A. Mansell A.S. Brady G. Brint E. Dunne A. Gray P. Harte M.T. McMurray D. Smith D.E. Sims J.E. Bird T.A. O'Neill L.A.J. Nature. 2001; 413: 78-83Crossref PubMed Scopus (1002) Google Scholar). We have also shown that the Mal protein can exist in different oligomeric states including dimers. This is also consistent with yeast two-hybrid experiments, which indicated the ability of Mal to form homodimers as well as heterodimers with MyD88. Unexpectedly, we observed that the Mal oligomers could be dissociated if they were prepared in the presence of high concentrations of ATP. The significance of this behavior is unclear; however, it suggests that Mal can adopt different conformers and that ATP can directly or indirectly convert these forms. Direct purine nucleotide binding has been proposed previously for TIR domains (34Hopp T.P. Protein Sci. 1995; 4: 1851-1859Crossref PubMed Scopus (20) Google Scholar). In addition, the TIR-fold is very similar to that of CheY, a bacterial chemotaxis protein that is transiently phosphorylated at an aspartate residue. This phosphorylation induces subtle changes in the CheY structure, particularly the change in conformation of a tyrosine residue in the loop between the fourth β-sheet and fourth α-helix. This conformational switch modulates the interaction of CheY with the flagellar motor, membrane sensor CheA, and regulator CheZ (35Zhu X.Y. Volz K. Matsumura P. J. Biol. Chem. 1997; 272: 23758-23764Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar). Given the remarkable structural conservation between CheY and the TIRs, it seems possible that the function of these homologous signaling domains also involves conformational changes induced by nucleotide binding or phosphotransfer. Finally, our analysis suggests that the Mal protein is related to Tube, an adaptor for the Drosophila Toll receptor. Until recently, it was thought that Tube was sufficient to establish signaling in the Drosophila Toll pathway. However, it is now clear that a direct homologue of vertebrate MyD88 is required in addition to Tube for both dorso-ventral patterning and for antifungal responses (15Tauszig-Delamasure S. Bilak H. Capovilla M. Hoffmann J.A. Imler J.L. Nat. Immunol. 2002; 3: 91-97Crossref PubMed Scopus (239) Google Scholar, 36Kambris Z. Bilak H. D'Alessandro R. Belvin M. Imler J.L. Capovilla M. EMBO Rep. 2003; 4: 64-69Crossref PubMed Scopus (22) Google Scholar), a situation reminiscent of the functional interdependence between vertebrate Mal and MyD88. Tube has a death domain sequence at the N-terminal, and this alone can restore some level of signaling by the Toll receptor (31Letsou A. Alexander S. Wasserman S.A. EMBO J. 1993; 12: 3449-3458Crossref PubMed Scopus (39) Google Scholar). The homology identified is principally located at the N-terminal of Mal preceding the TIR, a region with a number of potential phosphorylation sites, which could fulfill a regulatory role. In contrast to Tube, Mal does not have a death domain and must therefore couple to the downstream signaling pathway in a manner distinct from MyD88. The functional interrelationships of Mal, Tube, and Drosophila and vertebrate MyD88 homologues suggest that the C-terminal of Tube serves a role comparable with that of a TIR and may be a highly degenerated example of this fold, which cannot be detected from primary sequence identity. These studies point to a mechanism by which TIR adaptors can be recruited in response to activation of the receptor. A further understanding of this problem requires the experimental determination of structures for receptor and adaptor TIR complexes. The emergence of additional TLR signaling adaptors adds further complexity to this question, and it is clear that extensive in vitro studies are required to understand the precise mechanism by which TLRs assemble into higher order complexes. We thank the Science Foundation Ireland, Amgen Inc., and the UK Biotechnology and Biological Sciences Research Council." @default.
• W2016928596 created "2016-06-24" @default.
• W2016928596 creator A5001884348 @default.
• W2016928596 creator A5030082651 @default.
• W2016928596 creator A5079789061 @default.
• W2016928596 creator A5086513049 @default.
• W2016928596 date "2003-10-01" @default.
• W2016928596 modified "2023-10-16" @default.
• W2016928596 title "Structural Complementarity of Toll/Interleukin-1 Receptor Domains in Toll-like Receptors and the Adaptors Mal and MyD88" @default.
• W2016928596 cites W1513073936 @default.
• W2016928596 cites W1519843522 @default.
• W2016928596 cites W1955046737 @default.
• W2016928596 cites W1966772446 @default.
• W2016928596 cites W1969501356 @default.
• W2016928596 cites W1970349312 @default.
• W2016928596 cites W1976424894 @default.
• W2016928596 cites W1986191025 @default.
• W2016928596 cites W1986974750 @default.
• W2016928596 cites W1996120614 @default.
• W2016928596 cites W2000383223 @default.
• W2016928596 cites W2000464453 @default.
• W2016928596 cites W2004228538 @default.
• W2016928596 cites W2012738222 @default.
• W2016928596 cites W2019522924 @default.
• W2016928596 cites W2049245598 @default.
• W2016928596 cites W2056496184 @default.
• W2016928596 cites W2062308668 @default.
• W2016928596 cites W2079156871 @default.
• W2016928596 cites W2086607694 @default.
• W2016928596 cites W2089217951 @default.
• W2016928596 cites W2098336582 @default.
• W2016928596 cites W2110890402 @default.
• W2016928596 cites W2115956404 @default.
• W2016928596 cites W2116101489 @default.
• W2016928596 cites W2129319296 @default.
• W2016928596 cites W2140508442 @default.
• W2016928596 cites W2142209403 @default.
• W2016928596 cites W2147038697 @default.
• W2016928596 cites W2157165549 @default.
• W2016928596 cites W2161486446 @default.
• W2016928596 cites W2168058007 @default.
• W2016928596 cites W2171260427 @default.
• W2016928596 cites W2237784819 @default.
• W2016928596 cites W4239452276 @default.
• W2016928596 doi "https://doi.org/10.1074/jbc.m301742200" @default.
• W2016928596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12888566" @default.
• W2016928596 hasPublicationYear "2003" @default.
• W2016928596 type Work @default.
• W2016928596 sameAs 2016928596 @default.
• W2016928596 citedByCount "191" @default.
• W2016928596 countsByYear W20169285962012 @default.
• W2016928596 countsByYear W20169285962013 @default.
• W2016928596 countsByYear W20169285962014 @default.
• W2016928596 countsByYear W20169285962015 @default.
• W2016928596 countsByYear W20169285962016 @default.
• W2016928596 countsByYear W20169285962017 @default.
• W2016928596 countsByYear W20169285962018 @default.
• W2016928596 countsByYear W20169285962019 @default.
• W2016928596 countsByYear W20169285962020 @default.
• W2016928596 countsByYear W20169285962021 @default.
• W2016928596 countsByYear W20169285962022 @default.
• W2016928596 countsByYear W20169285962023 @default.
• W2016928596 crossrefType "journal-article" @default.
• W2016928596 hasAuthorship W2016928596A5001884348 @default.
• W2016928596 hasAuthorship W2016928596A5030082651 @default.
• W2016928596 hasAuthorship W2016928596A5079789061 @default.
• W2016928596 hasAuthorship W2016928596A5086513049 @default.
• W2016928596 hasBestOaLocation W20169285961 @default.
• W2016928596 hasConcept C136449434 @default.
• W2016928596 hasConcept C170493617 @default.
• W2016928596 hasConcept C185592680 @default.
• W2016928596 hasConcept C202269582 @default.
• W2016928596 hasConcept C203014093 @default.
• W2016928596 hasConcept C2776709828 @default.
• W2016928596 hasConcept C2777977768 @default.
• W2016928596 hasConcept C2778025104 @default.
• W2016928596 hasConcept C2778690821 @default.
• W2016928596 hasConcept C54355233 @default.
• W2016928596 hasConcept C55493867 @default.
• W2016928596 hasConcept C74172505 @default.
• W2016928596 hasConcept C86803240 @default.
• W2016928596 hasConcept C95444343 @default.
• W2016928596 hasConceptScore W2016928596C136449434 @default.
• W2016928596 hasConceptScore W2016928596C170493617 @default.
• W2016928596 hasConceptScore W2016928596C185592680 @default.
• W2016928596 hasConceptScore W2016928596C202269582 @default.
• W2016928596 hasConceptScore W2016928596C203014093 @default.
• W2016928596 hasConceptScore W2016928596C2776709828 @default.
• W2016928596 hasConceptScore W2016928596C2777977768 @default.
• W2016928596 hasConceptScore W2016928596C2778025104 @default.
• W2016928596 hasConceptScore W2016928596C2778690821 @default.
• W2016928596 hasConceptScore W2016928596C54355233 @default.
• W2016928596 hasConceptScore W2016928596C55493867 @default.
• W2016928596 hasConceptScore W2016928596C74172505 @default.
• W2016928596 hasConceptScore W2016928596C86803240 @default.
• W2016928596 hasConceptScore W2016928596C95444343 @default.
• W2016928596 hasIssue "42" @default.
• W2016928596 hasLocation W20169285961 @default.

• next